PMGC Holdings (ELAB) Current Leases (2022 - 2026)

PMGC Holdings (ELAB) posted Current Leases of $66171.0 for Q1 2026, down 73.28% sequentially from $247627.0 in Q4 2025.

PMGC Holdings (ELAB) Current Leases (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Current Leases for 5 years, with the latest figure at $66171.0 in Q1 2026.

Quarterly Current Leases changed N/A year-over-year to $66171.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66171.0 (changed N/A YoY) and the FY2025 annual result came in at $247627.0, changed N/A from the prior year.
Current Leases declined to $66171.0 in Q1 2026 per ELAB's latest filing, from $247627.0 in the prior quarter.
Over five years, Current Leases peaked at $140.9 million in Q3 2023 and troughed at $66171.0 in Q1 2026.
A 5-year average of $17.7 million and a median of $142531.5 in 2023 frame the typical range for Current Leases.
The sharpest annual moves came in 2023 and 2024: Current Leases jumped 31.08% in 2023, then sank 99.93% in 2024.
Over 5 years, Current Leases stood at $110616.0 in 2022, then soared by 31.08% to $145000.0 in 2023, then dropped by 28.75% to $103309.0 in 2024, then soared by 139.7% to $247627.0 in 2025, then slumped by 73.28% to $66171.0 in 2026.
According to Business Quant data, Current Leases over the past three periods registered $66171.0, $247627.0, and $103309.0 for Q1 2026, Q4 2025, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	45.93 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00	647,472.00

Download Data